+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)


Parkinson's Disease Drugs Market - Growth, Trends, and Forecast (2019 - 2024)

  • ID: 4591915
  • Report
  • March 2019
  • Region: Global
  • 111 pages
  • Mordor Intelligence
until Jun 30th 2020
1 of 4

Enquire about COVID-19 updates for this product.

Enquire Now


  • AbbVie Inc.
  • Boehringer Ingelheim
  • GlaxoSmithKline plc
  • Impax Laboratories Inc.
  • Merck & Co. Inc.
  • Mylan NV
  • MORE
Market Overview

Parkinson's disease is a chronic disorder that gradually leads to progressive deterioration of motor functions, caused by the loss of dopamine-producing brain cells. Parkinson’s disease drugs market is expected to witness significant growth, owing to the increasing cases of Parkinson’s disease, with the growth in aging population levels. Therefore, it may drastically result in increasing the market size during the forecast period. Pharmaceutical firms are developing new and improved therapies for Parkinson's disease (PD), and recently, there have been some major product launches in Parkinson disease therapeutics and other assistive therapeutics. For instance, Adamas Pharmaceuticals’ amantadine extended-release capsules / Gocovri launched in Jan 2018, which was the first drug indicated for dyskinesia developed due to long-term use of levodopa. Furthermore, most of the global firms have a robust drug pipeline for the treatment of Parkinson's disease, and as per the estimates, the forecast period may witness the launch of a few blockbuster drugs.

Scope of the Report

Parkinson’s disease drugs market has been segmented by the mechanism of action and geography. BY mechanism of action, the market studied is segmented into dopamine agonists, anticholinergic, MAO-B inhibitors, amantadine, carbidopa-levodopa, COMT inhibitors, and other mechanisms of action. By geography, the market is segmented into North America, Europe, Asia-Pacific, South America, and Middle East & Africa.

Key Market Trends

COMT (Catechol-O-Methyltransferase) Inhibitors are expected to Register Robust growth

Carbidopa-levodopa Therapy is the most effective medication for alleviating the motor symptoms of PD. However, it has been observed that this medication is not as effective as intended. Therefore, it is imperative that co-therapeutic agents, such as COMT (catechol-O-methyltransferase) inhibitors, are used along with carbidopa-levodopa therapy. The two most common COMT inhibitors, used in the treatment of Parkinson’s disease, are Comtan (entacapone) and Tasmar (tolcapone). Both these medications are available in the form of tablets. In addition, these medications are routinely prescribed in conjunction with carbidopa-levodopa therapy.

The United States Represents the Largest Market for Parkinson's Disease Therapeutics

According to the National Institute of Health, approximately 1.2 million people in the United States are predicted to have Parkinson’s disease by 2030. It is the second-most common neurodegenerative disorder in the United States. In addition, there are thousands of patients who go undetected. As the aging population levels continue to grow, the number of people suffering from Parkinson's disease (PD) will continue to grow, and this is expected to double by 2040. The sheer number of Parkinson’s disease patients, combined with the availability of reimbursements and high awareness, is boosting the growth of the market. Furthermore, the high cost of Parkinson's disease therapeutics in the United States also leads to significant market size in terms of revenue. The average cost of Parkinson’s medication is approximately USD 2,500 per year and Parkinson’s-related surgery can cost up to USD 100,000 per patient.

Competitive Landscape

Parkinson's disease drugs market is becoming highly competitive. The recent product launches and the high number of therapeutics in product pipelines of global pharmaceutical firms are contributing to the dynamic nature of the market. Several new product launches are expected during the forecast period, which may lead to significant changes in market shares of pharmaceutical firms currently active in the market.
Note: Product cover images may vary from those shown
2 of 4


  • AbbVie Inc.
  • Boehringer Ingelheim
  • GlaxoSmithKline plc
  • Impax Laboratories Inc.
  • Merck & Co. Inc.
  • Mylan NV
  • MORE
1.1 Study Deliverables
1.2 Study Assumptions
1.3 Scope of the Study



4.1 Market Overview
4.2 Market Drivers
4.2.1 Rising Geriatric Population
4.2.2 Recent Drug Approvals
4.2.3 Growing Awareness
4.3 Market Restraints
4.3.1 Generic Competition to Key Therapies
4.3.2 High Cost of Treatment
4.4 Porter's Five Forces Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry

5.1 By Mechanism of Action
5.1.1 Dopamine Agonists
5.1.2 Anticholinergic
5.1.3 MAO-B inhibitors
5.1.4 Amantadine
5.1.5 Carbidopa-levodopa
5.1.6 COMT Inhibitors
5.1.7 Other Mechanisms of Action
5.2 Geography
5.2.1 North America US Canada Mexico
5.2.2 Europe Germany UK France Italy Spain Rest of Europe
5.2.3 Asia-Pacific China Japan India Australia South Korea Rest of Asia-Pacific
5.2.4 Middle East & Africa GCC South Africa Rest of Middle East & Africa
5.2.5 South America Brazil Argentina Rest of South America

6.1 Company Profiles
6.1.1 Merck & Co. Inc.
6.1.2 Impax Laboratories Inc.
6.1.3 AbbVie Inc.
6.1.4 Mylan NV
6.1.5 Boehringer Ingelheim
6.1.6 GlaxoSmithKline plc
6.1.7 M Somerset Pharmaceuticals Inc.
6.1.8 Teva Pharmaceuticals Industries Ltd
6.1.9 Pfizer Inc.
6.1.10 Novartis AG

Note: Product cover images may vary from those shown
3 of 4


4 of 4
  • Merck & Co. Inc.
  • Impax Laboratories Inc.
  • AbbVie Inc.
  • Mylan NV
  • Boehringer Ingelheim
  • GlaxoSmithKline plc
  • M Somerset Pharmaceuticals Inc.
  • Teva Pharmaceuticals Industries Ltd
  • Pfizer Inc.
  • Novartis AG
Note: Product cover images may vary from those shown